Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ClearPoint Neuro, Inc. (CLPT)

ClearPoint Neuro Q2 revenue rises 18% to $10.9 million; net loss widens to $11.3 million

Mixed Impact 4 of 5 earnings Written later

ClearPoint Neuro reported second-quarter 2026 revenue of $10.9 million, up 18% from a year earlier, helped by the IRRA flow product, while its net loss more than doubled to $11.3 million. The company also set 2026 revenue guidance at $48.0 million to $52.0 million and said it is shifting spending toward clinical capacity and preclinical services, which shareholders should weigh against the higher losses and lower cash balance.

Key points

  • Q2 2026 revenue was $10.9 million, up from $9.2 million; biologics and drug delivery revenue fell 15% to $4.0 million.
  • Net loss was $11.3 million, or $0.38 per share, versus $5.8 million, or $0.21 per share, a year earlier.
  • Operating expenses rose 51% to $17.0 million, and cash and cash equivalents were $29.4 million at June 30, 2026, down from $45.9 million at December 31, 2025.
  • The company's 2026 revenue guidance is $48.0 million to $52.0 million, described as an adjustment to its revised priorities.

The filing

CompanyClearPoint Neuro, Inc. (CLPT)
Form8-K, current report
Filed with the SECAug 3, 2026, 4:05 PM ET
Accession number0001193125-26-330541

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.